XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

Separately, HC Wainwright reissued a “buy” rating and issued a $104.00 price target on shares of XOMA in a research report on Wednesday, March 19th.

XOMA Stock Down 0.9 %

Shares of NASDAQ:XOMA opened at $20.88 on Friday. The stock has a market capitalization of $250.12 million, a price-to-earnings ratio of -6.00 and a beta of 1.00. XOMA has a 1-year low of $19.92 and a 1-year high of $35.00. The company’s fifty day moving average is $24.37 and its two-hundred day moving average is $27.12. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA) last announced its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. Equities analysts anticipate that XOMA will post -1.41 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC grew its position in shares of XOMA by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 527 shares during the period. BNP Paribas Financial Markets increased its position in XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares during the period. New York State Common Retirement Fund increased its position in XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares during the period. Eversept Partners LP increased its position in shares of XOMA by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock worth $2,508,000 after purchasing an additional 1,128 shares during the period. Finally, Geode Capital Management LLC boosted its stake in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.